Aviceda Therapeutics
- Founded: 2018
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: Clin2/Clin3
- Therapy area: Geographic atrophy
- Drug types: OPH, HEP, LNG, NEU, NEU
- Lead product: AVD-104
- Product link: https://www.avicedarx.com/pipeline.html
- Funding: <10M
avicedarx.com linkedin.com job board
Short description:
Next generation of glyco-immune therapeutics
Drug notes:
Also Clin0 DME, Clin0 other eye conditions; 4 undisclosed programs RD/Clin0 IPF, liver fibrosis, myelofibrosis, lung inflammation, neurodegeneration, neuroinflammation, solid tumors
Long description:
Aviceda Therapeutics is developing glyco-therapeutics that modulate immune system dysfunction. The human glycome is far more diverse than the proteome or genome and plays a role in regulating innate immune checkpoints. Aviceda is using their technology platform to engineer highly optimized glyco-ligands that can modulate the self-recognition receptors on immune cells and convert them to a resolution state. Aviceda’s lead candidate, AVD-103, is being developed to target various immune system responses that contribute to pathology associated with dry age-related macular degeneration. AVD-104 is one of several glyco-immune therapeutics Aviceda is developing that are delivered via biodegradable nanoparticles.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com